Balance Sheet
Includes Current Assets, Liabilities and Stockholder's Equity
Latest Financial Results
Q1 2021
Quarter Ended Mar 31, 2021
$0.4M
Revenue for the first quarter ended March 31, 2021 was $0.4 million.
$32.4M
As of March 31, 2021, Adaptimmune had cash and cash equivalents of $32.4 million and Total Liquidity of $317.9 million.
Latest Annual Filing
For Fiscal Year Ending Dec 31, 2020
Report Links
For complete information regarding our financials, see our periodic filings